Screening test for Open Spina Bifida/ONTD, Trisomy 21/Down syndrome and Trisomy 18/Edward's syndrome.
Maternal serum specimens must be drawn prior to amniocentesis to avoid contamination with fetal blood.
Collect in serum separator tube with gel barrier.
Collect between 10.0 and 13.9 weeks gestation.
There is no risk assessment after the first draw. A specimen for the Integrated 2 must be collected and the overall risk for Down syndrome, trisomy 18 and open spina bifida is provided after the testing of the second blood sample, using information from the part 1 and part 2.
Allow blood to clot, avoiding hemolysis.
Separate serum from cells by centrifugation.
Transport spun tube to testing laboratory. Pour off is not advised.
Serum separator (SST) tube
Ambient (preferred) - 7 days
Refrigerated - 14 days
Frozen - 14 days
Gross hemolysis; gross lipemia; quantity not sufficient for analysis; improper specimen type.
An interpretive report will be provided
For test inquiries, call CMBP genetic services at 800-345- 4363. Client must provide fetal nuchal translucency (NT) measurement and crown rump length measurement. The NT measurement must be performed by a sonographer credentialed by the Fetal Medicine Foundation or other equivalent entity. The sonographer's credential/certification number must be provided. The following information also must be provided: patient's race, patient's weight, patient's date of birth, patient's insulin dependent diabetic status and the number of fetuses. Also indicate patient history (ie, prior Down syndrome pregnancy, ultrasound anomalies). Complete information is necessary to interpret the test. Serum testing is provided from 10.0 to 13.9 weeks of gestation. NT can be assessed when the CRL is 45 to 84 mm.